Topical Ivermectin Significantly Reduces Key Inflammatory Markers in Rosacea

Rosacea is a common, chronic inflammatory skin condition characterized by facial redness, visible blood vessels, and papules/pustules. While topical Ivermectin is an established treatment, its precise mechanisms beyond antiparasitic effects (targeting Demodex mites) are still being elucidated. This study aimed to evaluate the inhibitory effects of topical Ivermectin on specific biochemical markers of rosacea-specific inflammation and its impact on the skin microbiome.

Topical Ivermectin demonstrated significant anti-inflammatory effects and modulated the skin microbiome. Serine protease activity, a key inflammatory marker, was reduced by a remarkable 45% in the Ivermectin group compared to only 5% in the placebo group (p<0.001). Levels of the pro-inflammatory LL-37 cathelicidin peptide also saw a 30% reduction in Ivermectin-treated patients, while placebo showed no significant change. The most significant finding was a 45% reduction in serine protease activity, a key inflammatory marker, in the Ivermectin group compared to a mere 5% in the placebo group (p<0.001), highlighting its direct anti-inflammatory action. Furthermore, skin microbiome analysis revealed a 2.1-fold reduction in Demodex mite density and an increase in beneficial bacterial diversity in the Ivermectin group. Overall clinical improvement, as measured by Investigator Global Assessment (IGA) score, was observed in 70% of Ivermectin patients versus 25% of placebo patients (p<0.001).